Author: admin

Amyotrophic Lateral Sclerosis (ALS) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Procypra, Biogen, Ionis, AbbVie, Helixmith, Genuv, Kadimastem, QurAlis

“Delveinsight Business Research LLP”
As per DelveInsight, the Amyotrophic Lateral Sclerosis Market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.

DelveInsight’s “Amyotrophic Lateral Sclerosis (ALS) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis Market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Amyotrophic Lateral Sclerosis Market drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Amyotrophic Lateral Sclerosis Market treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Amyotrophic Lateral Sclerosis (ALS) Market: An Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Amyotrophic Lateral Sclerosis belongs to a broader group of disorders known as motor neuron diseases, which are caused by the gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to the muscles throughout the body.

Amyotrophic Lateral Sclerosis can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. The terms familial and genetic mean that this type of Amyotrophic Lateral Sclerosis is inherited. In families who have genetic Amyotrophic Lateral Sclerosis, there is an up to 50% chance that each child will inherit the gene and develop the disease.

No one test can provide a definitive diagnosis of Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis is primarily diagnosed based on a detailed history of the symptoms and signs observed by a physician during physical examination along with a series of tests to rule out other mimicking diseases. However, the presence of upper and lower motor neuron symptoms strongly suggests the presence of the disease. Tests that may help diagnose Amyotrophic Lateral Sclerosis are electromyography (EMG), nerve conduction study (NCS), and magnetic resonance imaging (MRI). 

Further tests to rule out other conditions may include blood and urine tests and a muscle biopsy. Medical problems that can produce similar symptoms to Amyotrophic Lateral Sclerosis, such as HIV, Lyme disease, multiple sclerosis (MS), the poliovirus, and the West Nile virus (WNV), should be considered when making a diagnosis.

Amyotrophic Lateral Sclerosis Market Key Facts

  • The United States accounts for the largest Amyotrophic Lateral Sclerosis market size compared to EU-4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan.

  • In the United States, the Amyotrophic Lateral Sclerosis market size is anticipated to rise from USD 369 million in 2021 during the forecast period.

  • Among the EU-4 countries, Germany had the largest Amyotrophic Lateral Sclerosis market size (USD 3 million) in 2021, while Spain had the smallest with USD 2 million.

  • Estimates show that the highest cases of Amyotrophic Lateral Sclerosis in the 7MM were in the United States, followed by EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan in the year 2021.

  • The US, in 2021 accounted for approximately 25,800+ diagnosed prevalent cases of Amyotrophic Lateral Sclerosis.

  • Among the EU-4 and the United Kingdom countries in 2021, Germany had the highest diagnosed prevalent cases of Amyotrophic Lateral Sclerosis with 5,300+ cases, followed by the UK (4,500+) and Italy (4,400+). In contrast, Spain had the lowest cases (3,200+) in 2021.

  • Current Amyotrophic Lateral Sclerosis Market dynamics are dominated by the use of RILUTEK, TIGLUTIK, EXSERVAN, NEUDEXTA, RADICAVA, RADICAVA ORS, RELYVRIO, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc.)

  • The therapies with the potential to get launched in the forecast period include Tofersen, ION363, NurOwn, Masitinib, and others. The launch of these therapies may increase market size in the coming years, assisted by an increasing patient pool of Amyotrophic Lateral Sclerosis patients.

Amyotrophic Lateral Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Amyotrophic Lateral Sclerosis Market pipeline therapies. It also thoroughly assesses the Amyotrophic Lateral Sclerosis Market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Amyotrophic Lateral Sclerosis Market drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Amyotrophic Lateral Sclerosis Market Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Amyotrophic Lateral Sclerosis Market epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Amyotrophic Lateral Sclerosis Market epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Amyotrophic Lateral Sclerosis Market Epidemiology, Segmented as –

  • Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Gender-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Age-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Type-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Mutation-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

  • Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]

Amyotrophic Lateral Sclerosis Market Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Amyotrophic Lateral Sclerosis Market or expected to be launched during the study period. The analysis covers the Amyotrophic Lateral Sclerosis Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Amyotrophic Lateral Sclerosis Market drugs based on their sale and market share.

The report also covers the Amyotrophic Lateral Sclerosis Market pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Amyotrophic Lateral Sclerosis Market companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Amyotrophic Lateral Sclerosis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast

Amyotrophic Lateral Sclerosis Market Therapeutics Analysis

Currently, there is no cure for Amyotrophic Lateral Sclerosis and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of Amyotrophic Lateral Sclerosis includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. Moreover, there are five drugs approved by the US FDA to treat Amyotrophic Lateral Sclerosis, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK. 

Medications are also prescribed to help manage symptoms of Amyotrophic Lateral Sclerosis, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar effect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation.

To further improve the treatment outlook, companies across the globe are thoroughly working toward the development of new treatment therapies for Amyotrophic Lateral Sclerosis. Some of the key players in the therapeutic market of Amyotrophic Lateral Sclerosis at a global level are Cytokinetics, Orphazyme, Orion, Brainstorm Cell Therapeutics, Biogen, AB Science, Ionis Pharmaceuticals, Clene Nanomedicine, Immunity Pharma, MediciNova, Biohaven Pharmaceuticals, and others. 

Amyotrophic Lateral Sclerosis Market Companies Actively Working in the Therapeutics Market Include:

Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and many others.

Emerging and Marketed Amyotrophic Lateral Sclerosis Market Therapies Covered in the Report Include:

  • Tofersen: Biogen/Ionis Pharmaceuticals

  • RNS60: Revalesio Corporation

  • ANX005: Annexon

  • Masitinib: AB Science

  • NurOwn: Brainstorm-Cell Therapeutics

  • Gold Nanocrystals/CNM-Au8: Clene Nanomedicine

  • Verdiperstat: Biohaven Pharmaceuticals

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Amyotrophic Lateral Sclerosis Market Competitive Intelligence Analysis

4. Amyotrophic Lateral Sclerosis Market Overview at a Glance

5. Amyotrophic Lateral Sclerosis Market Disease Background and Overview

6. Amyotrophic Lateral Sclerosis Market Patient Journey

7. Amyotrophic Lateral Sclerosis Market Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Amyotrophic Lateral Sclerosis Market Treatment Algorithm, Current Treatment, and Medical Practices

9. Amyotrophic Lateral Sclerosis Market Unmet Needs

10. Key Endpoints of Amyotrophic Lateral Sclerosis Market Treatment

11. Amyotrophic Lateral Sclerosis Marketed Therapies

12. Amyotrophic Lateral Sclerosis Market Emerging Drugs and Latest Therapeutic Advances

13. Amyotrophic Lateral Sclerosis Market Seven Major Market Analysis

14. Attribute Analysis

15. Amyotrophic Lateral Sclerosis Market Outlook (In US, EU5, and Japan)

16. Amyotrophic Lateral Sclerosis Market Companies Active in the Market

17. Amyotrophic Lateral Sclerosis Market Access and Reimbursement Overview

18. KOL Views on the Amyotrophic Lateral Sclerosis Market

19. Amyotrophic Lateral Sclerosis Market Drivers

20. Amyotrophic Lateral Sclerosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Chronic Refractory Gout Market

“Chronic Refractory Gout Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Refractory Gout market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chronic Refractory Gout market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis (ALS) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Procypra, Biogen, Ionis, AbbVie, Helixmith, Genuv, Kadimastem, QurAlis

Beta Thalassemia Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – DelveInsight | Novartis, Merck, DisperSol, Bluebird Bio, Ionis, Imara, CRISPR Therapeutics

“Delveinsight Business Research LLP”
As per DelveInsight, the Beta Thalassemia Market is anticipated to evolve immensely in the coming years owing to the increasing prevalence of Beta Thalassemia, improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.

DelveInsight’s “Beta Thalassemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Beta Thalassemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Beta Thalassemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Beta Thalassemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Beta Thalassemia: An Overview

Beta thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.

Beta thalassemia includes three primary forms: thalassemia major (variably referred to as “Cooley’s Anemia” and “Mediterranean Anemia), thalassemia intermediate, and thalassemia minor (also called “beta thalassemia carrier,” “beta thalassemia trait” or “heterozygous beta thalassemia”).

Most beta thalassemia cases are caused by a mutation in the HBB gene. In extremely rare cases, a loss of genetic material (deletion) that includes the HBB gene causes the disorder. Individuals with beta thalassemia minor have a mutation in one HBB gene and are carriers for the disorder. Individuals with beta thalassemia intermedia or major have mutations in both HBB genes.

General symptoms of severe untreated β-thalassemia include severe anemia, with a Hb level of 3−7 g/dL, massive hepatosplenomegaly, severe growth retardation, and bony deformities. People with beta thalassemia major or intermediate usually have a buildup of iron in the body, either from the disease itself or from repeated blood transfusions. Excess iron can damage the heart, liver, and endocrine system. People with the minor form of Beta Thalassaemia have small red blood cells but no symptoms.

Beta Thalassemia Market Key Facts

  • Many studies point towards a similar fact that about 1.5% of the global population (80–90 million people) has been estimated to be the carriers of beta-thalassemia.

  • According to Chamberlain et al. (2021), in Europe, the estimated beta-thalassemia prevalence was 0.16/100,000 in Spain and in the United States, it was 5.7/100,000.

  • As per Kattamis et al. (2020), the prevalence of β‐thalassemia major was observed to be 0.3 per 100,000 in different parts of the United Kingdom.

  • As per the studies conducted by Khaled et al. (2023), the prevalence of beta-thalassemia in France increased from 0.6 in the period 2005–2008 to 0.8 in 2019 per 100,000. Whereas, the prevalence of beta-thalassemia in Spain was observed to be 0.2/100,000 people in the 2014–2017 period duration.

  • According to the National Haemoglobinopathy Registry (NHR) annual report 2020, there were >900 beta-thalassemia major patients and >200 beta-thalassemia intermediate patients living in the UK.

Beta Thalassemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Beta Thalassemia pipeline therapies. It also thoroughly assesses the Beta Thalassemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Beta Thalassemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Beta Thalassemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Beta Thalassemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Beta Thalassemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Beta Thalassemia Epidemiology, Segmented as –

  • Total Prevalent Cases of Beta Thalassemia in the 7MM [2019–2032]

  • Diagnosed Prevalent Cases of Beta Thalassemia in the 7MM [2019–2032]

  • Type-specific Diagnosed Prevalent Cases of Beta Thalassemia in the 7MM [2019–2032]

  • Treatable Cases of Beta Thalassemia in the 7MM [2019–2032]

Beta Thalassemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Beta Thalassemia market or expected to be launched during the study period. The analysis covers the Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Beta Thalassemia drugs based on their sale and market share.

The report also covers the Beta Thalassemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Beta Thalassemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Beta Thalassemia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/beta-thalassemia-market

Beta Thalassemia Therapeutics Analysis

Blood transfusions are the primary therapy for β-thalassemia, but the frequency depends upon the severity of the disease. Blood transfusions expose patients to other complications and risks, including iron overload, infections, cardiac disease, etc. Other treatment strategies include iron chelation therapy, splenomegaly/splenectomy, growth abnormalities, bone deformities treatment, and more.

To counter unmet market needs and provide better treatment choices for beta-thalassemia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period. Currently, CRISPR Therapeutics is leading the therapeutics market with its Beta-thalassaemia drug candidates in the most advanced stage of clinical development.

In November 2019, the FDA approved REBLOZYL for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions. It is a recombinant fusion protein that binds several endogenous TGF-β superfamily ligands, diminishing Smad2/3 signaling. Luspatercept-aamt promoted erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in mice.

In August 2022, the FDA approved ZYNTEGLO (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. ZYNTEGLO is a one-time gene therapy product administered as a single dose. Each dose of ZYNTEGLO is a customized treatment created using the patient’s own cells (bone marrow stem cells) that are genetically modified to produce functional beta-globin.

Beta Thalassemia Companies Actively Working in the Therapeutics Market Include

  • Novartis

  • Merck

  • Bristol Myers Squibb

  • Chiesi Farmaceutici S.p.A

  • Bluebird Bio

  • Agios Pharmaceuticals

  • Imara Inc.

  • CRISPR Therapeutics

  • Vertex Pharmaceuticals

  • Vifor Pharma

  • Ionis Pharmaceuticals

  • Forma Therapeutics

  • DisperSol Technologies

  • SILENCE Therapeutics

And Many Others

Emerging and Marketed Beta Thalassemia Therapies Covered in the Report Include:

  • Zynteglo (LentiGlobin BB305): Bluebird Bio

  • Mitapivat (AG-348): Agios Pharmaceuticals

  • CTX001: CRISPR Therapeutics

  • VIT-2763: CSL Vifor

  • Emeramide: EmeraMed

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/beta-thalassemia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Beta Thalassemia Competitive Intelligence Analysis

4. Beta Thalassemia Market Overview at a Glance

5. Beta Thalassemia Disease Background and Overview

6. Beta Thalassemia Patient Journey

7. Beta Thalassemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Beta Thalassemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Beta Thalassemia Unmet Needs

10. Key Endpoints of Beta Thalassemia Treatment

11. Beta Thalassemia Marketed Therapies

12. Beta Thalassemia Emerging Drugs and Latest Therapeutic Advances

13. Beta Thalassemia Seven Major Market Analysis

14. Attribute Analysis

15. Beta Thalassemia Market Outlook (In US, EU5, and Japan)

16. Beta Thalassemia Companies Active in the Market

17. Beta Thalassemia Access and Reimbursement Overview

18. KOL Views on the Beta Thalassemia Market

19. Beta Thalassemia Market Drivers

20. Beta Thalassemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/beta-thalassemia-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Complicated Urinary Tract Infections Market

“Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Complicated Urinary Tract Infections market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Beta Thalassemia Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – DelveInsight | Novartis, Merck, DisperSol, Bluebird Bio, Ionis, Imara, CRISPR Therapeutics

Septic Shock Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Adrenomed, AM-Pharma, Atox Bio, Inotrem, LaJolla Pharma, Pharmazz, Vivacelle Bio

“Delveinsight Business Research LLP”
As per DelveInsight, the Septic Shock Market is anticipated to evolve immensely in the coming years owing to the increasing incident population and the launch of emerging therapies in the 7MM.

DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Septic Shock market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Septic Shock drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Septic Shock treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Septic Shock: An Overview

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities. Anyone affected by an infection, severe injury, or serious non-communicable disease can progress to sepsis, but vulnerable populations are at higher risk, including older persons, pregnant or recently pregnant women, neonates, hospitalized patients, patients in intensive care units, etc.

The symptoms of sepsis include fever or low temperature and shivering, altered mental status, difficulty breathing/rapid breathing, increased heart rate, weak pulse/low blood pressure, low urine output, cyanotic or mottled skin, cold extremities, and extreme body pain or discomfort.

The risk of septic shock is higher in newborns and infants, elderly people, pregnant women, and individuals with chronic diseases. The chronic diseases that increase the risk of septic shock include diabetes, cirrhosis, cancer, AIDS/HIV, and kidney and heart disease.

The pathogenesis involves a complex response of cellular activation that triggers the release of a multitude of proinflammatory mediators. This inflammatory response causes activation of leukocytes and endothelial cells, as well as activation of the coagulation system. Cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) are central to the pathophysiology of septic shock and act synergistically to induce hypotension in experimental models, a number of other vital mediators are also known to play a major role including high-mobility group box 1 (HMGB1) protein.

Septic Shock Market Key Facts

  • As per the study conducted by Hari et al. (2017), titled “Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database” shows that the sepsis-2 septic shock and sepsis-3 septic shock accounted for 23.4%, and 6.0%, respectively, of admissions to adult general ICUs in England over the five year period.

  • Sepsis-2 septic shock accounted for three-quarters of the severe sepsis population, and the extrapolated population incidence increased from 69 to 79 per 100,000 person-years. In contrast, sepsis-3 septic shock was only one-fifth of the sepsis population and with minimal change in the extrapolated population incidence over the 5-year period (approximately 19 per 100,000 person-years).

  • The study conducted by Quenot et al. (2013), titled “The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study,” among patients admitted to participating ICUs between October 2009 and September 2011, 13.7% of patients had septic shock.

Septic Shock Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Septic Shock pipeline therapies. It also thoroughly assesses the Septic Shock market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Septic Shock drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Septic Shock Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Septic Shock epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Septic Shock epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Septic Shock Epidemiology, Segmented as –

  • Total Incident Cases of Septic Shock in the 7MM [2019–2032]

  • Gender-specific Incident Cases of Septic Shock in the 7MM [2019–2032]

  • Treatable Cases of Septic Shock in the 7MM [2019–2032]

Septic Shock Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Septic Shock market or expected to be launched during the study period. The analysis covers the Septic Shock market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Septic Shock drugs based on their sale and market share.

The report also covers the Septic Shock pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Septic Shock companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Septic Shock Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/septic-shock-market

Septic Shock Therapeutics Analysis

The medications used in septic shock include intravenous antibiotics, vasopressors, inotropic drugs, insulin, and corticosteroids.

Broad-spectrum antibiotics are administered in patients experiencing septic shock (within 1 h of recognition of septic shock) and sepsis without septic shock. The choice of antibiotics depends on the patient’s immunity, the source of the infection, and the causative microorganism. 

Typically, broad-spectrum gram-positive and gram-negative bacterial coverage is used initially; immunocompromised patients should also receive an empiric antifungal drug. Common antibiotics for empiric gram-positive coverage include vancomycin and linezolid. Empiric gram-negative antibiotics include broad-spectrum penicillins (piperacillin, tazobactam), 3rd- or 4th-generation cephalosporins, imipenems, and aminoglycosides.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Septic Shock. Currently, Adrenomed is leading the therapeutics with its Septic Shock drug candidates in the most advanced stage of clinical development.

Septic Shock Companies Actively Working in the Therapeutics Market Include

  • Adrenomed AG

  • AM-Pharma

  • Atox Bio

  • Inotrem

  • LaJolla Pharmaceutical Company

  • MYND LifeSciences

  • Northern Therapeutics

  • Pharmazz

  • Vivacelle Bio

And Many Others

Emerging and Marketed Septic Shock Therapies Covered in the Report Include:

  • Adrecizumab: Adrenomed

  • Nangibotide: Inotrem

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/septic-shock-market

 Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Septic Shock Competitive Intelligence Analysis

4. Septic Shock Market Overview at a Glance

5. Septic Shock Disease Background and Overview

6. Septic Shock Patient Journey

7. Septic Shock Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Septic Shock Treatment Algorithm, Current Treatment, and Medical Practices

9. Septic Shock Unmet Needs

10. Key Endpoints of Septic Shock Treatment

11. Septic Shock Marketed Therapies

12. Septic Shock Emerging Drugs and Latest Therapeutic Advances

13. Septic Shock Seven Major Market Analysis

14. Attribute Analysis

15. Septic Shock Market Outlook (In US, EU5, and Japan)

16. Septic Shock Companies Active in the Market

17. Septic Shock Access and Reimbursement Overview

18. KOL Views on the Septic Shock Market

19. Septic Shock Market Drivers

20. Septic Shock Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/septic-shock-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Congestive Heart Failure Market

“Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Congestive Heart Failure market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Congestive Heart Failure market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Septic Shock Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Adrenomed, AM-Pharma, Atox Bio, Inotrem, LaJolla Pharma, Pharmazz, Vivacelle Bio

Molluscum Contagiosum Pipeline Analysis (2024) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Novan, Veloce Biopharma, Verrica Pharma, Santalis

“Delveinsight Business Research LLP”
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Molluscum Contagiosum therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Molluscum Contagiosum Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Molluscum Contagiosum Therapeutics Market. 

The report provides a detailed description of the Molluscum Contagiosum drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Molluscum Contagiosum Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the key companies that are developing Molluscum Contagiosum therapies.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Molluscum Contagiosum treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging Molluscum Contagiosum drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Molluscum Contagiosum treatment market.

Molluscum Contagiosum Therapeutics Analysis

There are approx. 10+ key companies developing therapies for Molluscum Contagiosum. Currently, Novan Inc. is leading the therapeutics market with its Molluscum Contagiosum drug candidates in the most advanced stage of clinical development.

Molluscum Contagiosum Companies in the Therapeutics Market Include:

  • Novan

  • Veloce Biopharma

  • Verrica Pharmaceuticals

  • Santalis Healthcare

And Many Others

Emerging and Marketed Molluscum Contagiosum Therapies Covered in the Report Include:

  • SB 206 (Berdazimer Sodium): Novan Inc

  • VBP-245 (Povidone Iodine Topical): Veloce Biopharma

  • VP-102: Verrica Pharmaceuticals

And Many More

Get an in-depth Assessment of the Emerging Therapies and Molluscum Contagiosum Companies Actively Working in the Market @

https://www.delveinsight.com/sample-request/molluscum-contagiosum-pipeline-insight

The Report Covers the Emerging Molluscum Contagiosum Therapies Under Different Phases of Clinical Development Like – 

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Molluscum Contagiosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Subcutaneous

  • Intravenous

  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Small molecule

Request for Sample PDF to Understand More About the Molluscum Contagiosum Treatment Outlook and Future Perspectives @

https://www.delveinsight.com/sample-request/molluscum-contagiosum-pipeline-insight

Table of Content

1. Report Introduction

2. Executive Summary

3. Molluscum Contagiosum Current Treatment Patterns

4. Molluscum Contagiosum – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Molluscum Contagiosum Late-Stage Products (Phase-III)

7. Molluscum Contagiosum Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Molluscum Contagiosum Discontinued Products

13. Molluscum Contagiosum Product Profiles

14. Molluscum Contagiosum Companies

15. Molluscum Contagiosum Drugs

16. Dormant and Discontinued Products

17. Molluscum Contagiosum Unmet Needs

18. Molluscum Contagiosum Future Perspectives

19. Molluscum Contagiosum Analyst Review  

20. Appendix

21. Report Methodology

Get Detailed Insights About the Reports Offerings @ 

https://www.delveinsight.com/sample-request/molluscum-contagiosum-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Acute Pyelonephritis Market

“Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Acute Pyelonephritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Molluscum Contagiosum Pipeline Analysis (2024) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Novan, Veloce Biopharma, Verrica Pharma, Santalis

Lithium-ion Battery Market Poised for Remarkable Growth, Predicted to Reach USD 187.1 Billion by 2032

“Lithium-ion Battery Market”
The global Lithium-ion Battery Market in terms of revenue was estimated to be worth $56.8 billion in 2023 and is poised to reach $187.1 billion by 2032, growing at a CAGR of 14.2% during the forecast period.

CHICAGO, Jan 08, 2024 – The global Lithium-ion Battery Market is on the brink of significant growth, with a projected increase from USD 56.8 billion in 2023 to USD 187.1 billion by 2032, reflecting an impressive Compound Annual Growth Rate (CAGR) of 14.2% during the forecast period. These insights are detailed in a comprehensive report by MarketsandMarkets, a leading market research and consulting firm.

Because of their high energy density, extended cycle life, and adaptability, lithium-ion batteries are currently the go-to energy storage option in a number of sectors, including renewable energy, electric vehicles, and consumer electronics. Advances in battery technology, the growing popularity of renewable energy storage solutions, and the growing demand for electric vehicles are some of the factors driving the anticipated rise in the lithium-ion battery market. The study profiles major participants in the global lithium-ion battery market and examines important market segments, growth factors, obstacles, and prospects.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49714593

Lithium-ion Battery Market

Key Segments:

Type Segment: Lithium-ion batteries come in various types, including lithium cobalt oxide (LiCoO2), lithium manganese oxide (LiMn2O4), lithium iron phosphate (LiFePO4), and others, each catering to specific applications and performance requirements.

Application Segment: The market includes diverse applications, such as electric vehicles, consumer electronics, energy storage systems, and industrial applications, showcasing the broad utility of Lithium-ion batteries.

End-User Segment: Lithium-ion batteries serve different end-user industries, including automotive, electronics, power, and energy, reflecting the widespread adoption across sectors.

Inquiry Before Buying @
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=49714593

Growth Drivers:

Rising Demand for Electric Vehicles: The increasing global demand for electric vehicles, driven by environmental concerns and government incentives, fuels the growth of the Lithium-ion Battery market as a key component in electric vehicle powertrains.

Advancements in Battery Technologies: Ongoing advancements in Lithium-ion battery technologies, including improvements in energy density, safety features, and cost reductions, contribute to the expanded use of lithium-ion batteries across industries.

Increased Adoption of Renewable Energy Storage: The growing adoption of renewable energy sources and the need for efficient energy storage solutions propel the demand for Lithium-ion batteries in grid storage applications, providing stability and reliability to renewable energy systems.

Challenges:

Supply Chain Constraints: Addressing supply chain constraints, including the availability of raw materials such as lithium and cobalt, poses challenges for lithium-ion battery manufacturers to meet the growing demand.

Safety Concerns and Regulatory Compliance: Ensuring the safety of lithium-ion batteries and compliance with stringent regulations present challenges, requiring continuous efforts to enhance battery safety and reliability.

Opportunities:

Development of Solid-State Batteries: The ongoing research and development of solid-state batteries present opportunities for innovation in Lithium-ion battery technology, offering potential improvements in safety, energy density, and cycle life.

Integration with Internet of Things (IoT): The integration of Lithium-ion batteries with IoT technologies creates opportunities for smart battery management systems, enabling remote monitoring, optimization, and predictive maintenance.

View detailed Table of Content here –
https://www.marketsandmarkets.com/Market-Reports/lithium-ion-battery-market-49714593.html

Key Players:

The report identifies key players in the global Lithium-ion Battery market, including:

LG Chem Ltd.: A South Korean multinational chemical company, LG Chem is a leading manufacturer of Lithium-ion batteries for a wide range of applications, including electric vehicles and energy storage systems.

Panasonic Corporation: A Japanese multinational electronics company, Panasonic is a key player in the Lithium-ion Battery market, supplying batteries for electric vehicles, consumer electronics, and industrial applications.

Samsung SDI Co., Ltd.: A subsidiary of Samsung Group, Samsung SDI is a major player in the Lithium-ion Battery market, producing batteries for electric vehicles, energy storage systems, and consumer electronics.

BYD Company Ltd.: A Chinese multinational conglomerate, BYD is actively involved in the manufacturing of Lithium-ion batteries for electric vehicles, renewable energy storage, and consumer electronics.

Because of the growing electrification of vehicles, developments in battery technology, and the growing usage of renewable energy sources, the global lithium-ion battery market is poised for spectacular growth. Lithium-ion batteries are anticipated to be essential to sustaining the future as long as industries continue to place a high priority on sustainability and energy efficiency.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lithium-ion-battery-market-49714593.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lithium-ion Battery Market Poised for Remarkable Growth, Predicted to Reach USD 187.1 Billion by 2032

Glioblastoma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioblastoma Pipeline Report

  • DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
  • The leading Glioblastoma Companies working in the market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
  • January 2024: Hoffmann-La Roche announced a study of Phase 1 clinical trials for RO7428731. This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).
  • December 2023: Boehringer Ingelheim announced a study of Phase 1 clinical trials for BI 907828 (Brigimadlin). This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery. Part 2 is open to people who already had such a brain surgery.
  • December 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY2157299 monohydrate, and Lomustine. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer.
  • December 2023: Cantex Pharmaceuticals announced a study of Phase 2 clinical trials for Azeliragon. This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There’s no cure for glioblastoma, which is also known as glioblastoma multiforme.
  • December 2023: Enterome announced a study of Phase 1 & 2 clinical trials for Multiple dose of EO2401. The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

 

Request a sample and discover the recent advances in Glioblastoma Drugs @ Glioblastoma Pipeline Outlook Report

 

In the Glioblastoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the Glioblastoma pipeline products under development.

 

Glioblastoma Overview

The glioblastoma multiforme preferentially invades along myelinated axons, vascular basement membranes, and the subependyma, mostly occurring in the subcortical matter of the cerebrum (65%). Within the cerebrum, the tumors proliferate through the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes. However, tumor formation is rarely isolated exclusively to one of these lobes, instead presenting in a combination of these lobes within the cerebrum. GBM also forms in the hypothalamus-thalamus area (20%) and the cerebellum and posterior fossa (15%).

 

Find out more about Glioblastoma Analysis @ Glioblastoma Drugs

 

Glioblastoma Emerging Drugs Profile

  • Enzastaurin: Denovo BioPharma
  • Tofacitinib: Pfizer
  • VT1021: Vigeo Therapeutics
  • Varlilumab: Celldex Therapeutics
  • Debio 0123: Debiopharm
  • PRT3645: Prelude Therapeutics

 

Glioblastoma Therapeutics Assessment

There are approx. 195+ Glioblastoma companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma. The Glioblastoma pipeline report proffers an integral view of the emerging Glioblastoma segmented by stage, product type, molecule type, and route of administration.

 

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Dive deep into rich insights for new Glioblastoma, visit @ Glioblastoma Treatment Landscape

 

Glioblastoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

 

For further information on the Glioblastoma Pipeline Therapeutics, reach out @ Glioblastoma Therapeutics Segmentation

 

Table of Content

  1. Introduction
  2. Glioblastoma Executive Summary
  3. Glioblastoma: Overview
  4. Glioblastoma Pipeline Therapeutics
  5. Glioblastoma Therapeutic Assessment
  6. Glioblastoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Varlilumab: Celldex Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PRT3645: Prelude Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ELC-401: Elicera Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glioblastoma Key Companies
  21. Glioblastoma Key Products
  22. Glioblastoma- Unmet Needs
  23. Glioblastoma- Market Drivers and Barriers
  24. Glioblastoma- Future Perspectives and Conclusion
  25. Glioblastoma Analyst Views
  26. Glioblastoma Key Companies
  27. Appendix

 

Find out more about Glioblastoma Therapeutics Assessment @ Glioblastoma Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Chimeric Antigen Receptor T-Cell Therapy Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ CAR-T Therapy companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Therapy Pipeline Report

  • DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
  • The leading CAR-T Therapy companies working in the market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
  • Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
  • January 2024: Janssen Research & Development LLC announced a study of Phase 2 clinical trials for JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib and Dexamethasone. The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
  • January 2024: CARsgen Therapeutics Co. Ltdannounced a study of Phase 1 & 2 clinical trials for CT041 autologous CAR T-cell injection. This study is an open, multicenter, Phase Ib/II clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting Claudin18.2 (CLDN18.2) (CT041 autologous CAR T) in subjects with CLDN18.2 expression-positive, advanced gastric/esophagogastric conjugate adenocarcinoma that has failed at least 2 prior lines therapy and advanced pancreatic cancer that has failed at least 1 prior line therapy. The purpose is to evaluate the efficacy, safety and pharmacokinetics There are two stages in the study. Phase Ib stage is dose escalation and dose expansion study, and Phase II stage is to verify the efficacy and safety of CT041 treatment.
  • January 2024: Caribou Biosciences Inc. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
  • December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

 

Request a sample and discover the recent advances in CAR-T Therapy Drugs @ CAR-T Therapy Pipeline Outlook Report

 

In the CAR-T Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth CAR-T Therapy commercial assessment and clinical assessment of the CAR-T Therapy pipeline products under development.

 

CAR-T Therapy Overview

CAR T cell therapy uses T cells engineered with CARs to treat cancer. The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, and then infuse the resulting CAR T cells into patients to attack their tumors. Cancer Immunotherapy utilizes and enhances the immune system’s standard capacity and is considered one of the most promising approaches for treating various diseases (including cancer, autoimmune diseases, and allergic–hypersensitivity reactions) are severe.

 

Find out more about CAR-T Therapy Analysis @ CAR-T Therapy Drugs

 

CAR-T Therapy Emerging Drugs Profile

  • CT053: Carsgen Therapeutics
  • Descartes-08: Cartesian Therapeutics
  • ALLO-501A: Allogene Therapeutics
  • CTX110: CRISPR Therapeutics
  • IMPT 314: ImmPACT Bio
  • ALLO-715: Allogene Therapeutics

 

CAR-T Therapy Therapeutics Assessment

There are approx. 200+ CAR-T Therapy companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics. The CAR-T Therapy pipeline report proffers an integral view of the emerging CAR-T Therapy segmented by stage, product type, molecule type, and route of administration.

 

CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Dive deep into rich insights for new CAR-T Therapy, visit @ CAR-T Therapy Treatment Landscape

 

CAR-T Therapy Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Scope of the CAR-T Therapy Pipeline Report

  • Coverage- Global
  • CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
  • CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.

 

For further information on the CAR-T Therapy Pipeline Therapeutics, reach out @ CAR-T Therapy Therapeutics Segmentation

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. CAR-T Therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. CAR-T Therapy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Registered)
  8. CT053: Carsgen Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Descartes-08: Cartesian Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ALLO-715: Allogene Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ACLX 003: Arcellx
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. CAR-T Therapy Key Companies
  21. CAR-T Therapy Key Products
  22. CAR-T Therapy- Unmet Needs
  23. CAR-T Therapy- Market Drivers and Barriers
  24. CAR-T Therapy- Future Perspectives and Conclusion
  25. CAR-T Therapy Analyst Views
  26. CAR-T Therapy Key Companies
  27. Appendix

 

Find out more about CAR-T Therapy Therapeutics Assessment @ CAR-T Therapy Preclinical and Discovery Stage Products

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chimeric Antigen Receptor T-Cell Therapy Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Glioma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight’s, “Glioma Pipeline Insight 2023” report provides comprehensive insights about 200+ Glioma companies and 220+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioma Pipeline Report

  • DelveInsight’s Glioma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Glioma treatment.
  • The leading Glioma companies working in the market include Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio Inc., BioMimetix, CNS Pharmaceuticals, and others.
  • Promising Glioma Pipeline Therapies in the various stages of development include DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
  • December 2023: Day One Biopharmaceuticals Inc. announced a study of Phase 3 clinical trials for DAY101 and Chemotherapeutic Agent. This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
  • December 2023: Daiichi Sankyo Co. Ltd announced a study of Phase 2 clinical trials for DS-1001b. This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
  • December 2023: Chimerixannounced a study of Phase 3 clinical trials for ONC201. This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
  • December 2023: Aveta Biomics Inc. announced a study of Phase 1 & 2 clinical trials for APG-157. The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma who have previously progressed on bevacizumab alone.
  • December 2023: Boehringer Ingelheimannounced a study of Phase 1 clinical trials for BI 764532. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer.

 

Request a sample and discover the recent advances in Glioma Drugs @ Glioma Pipeline Outlook Report

 

In the Glioma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Glioma clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the Glioma pipeline products under development.

 

Glioma Overview

A glioma is a tumor that forms in the brain or spinal cord. Neuroglial cells also known as glial cells or glia are quite different from nerve cells. They do not participate directly in synaptic interactions and electrical signaling, although their supportive functions help define synaptic contacts and maintain the signaling abilities of neurons. Glia are more numerous than nerve cells in the brain, outnumbering them by a ratio of perhaps 3 to 1. Although glial cells also have complex processes extending from their cell bodies, they are generally smaller than neurons, and they lack axons and dendrites.

 

Find out more about Glioma Analysis @ Glioma Drugs

 

Glioma Emerging Drugs Profile

  • Tofacitinib: Pfizer
  • Enzastaurin: Denovo BioPharma
  • MDNA55: Medicenna Therapeutics, Inc.
  • Sym004: Symphogen A/S
  • MN-166: MediciNova

 

Glioma Therapeutics Assessment

There are approx. 200+ Glioma companies which are developing the therapies for Glioma Disease. The Glioma companies which have their Glioma Disease drug candidates in the most advanced stage, i.e. Phase III include, Denovo BioPharma. The Glioma pipeline report proffers an integral view of the emerging Glioma segmented by stage, product type, molecule type, and route of administration.

 

Glioma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Dive deep into rich insights for new Glioma, visit @ Glioma Treatment Landscape

 

Glioma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Scope of the Glioma Pipeline Report

  • Coverage- Global
  • Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio Inc., BioMimetix, CNS Pharmaceuticals, and others.
  • Glioma Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.

 

For further information on the Glioma Pipeline Therapeutics, reach out @ Glioma Therapeutics Segmentation

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glioma Disease: Overview
  4. Glioma Pipeline Therapeutics
  5. Glioma Therapeutic Assessment
  6. Glioma Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MDNA55: Medicenna Therapeutics, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Zotiraciclib: Adastra Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. RGN6024: Reglagene, Inc.
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glioma Disease Key Companies
  21. Glioma Disease Key Products
  22. Glioma Disease- Unmet Needs
  23. Glioma Disease- Market Drivers and Barriers
  24. Glioma Disease- Future Perspectives and Conclusion
  25. Glioma Disease Analyst Views
  26. Glioma Disease Key Companies
  27. Appendix

 

Find out more about Glioma Therapeutics Assessment @ Glioma Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Gastric Cancer Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight’s, “Gastric Cancer Pipeline Insight 2023” report provides comprehensive insights about 180+ Gastric Cancer companies and 200+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gastric Cancer Pipeline Report

  • DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 180+ companies working to develop 200+ pipeline Gastric Cancer.
  • The leading Gastric Cancer companies working in the market include Linton Pharm Co.Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, TaihoOncology Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co. Ltd, Shanghai MiracogenInc., RemeGen Co Ltd., Idience Co. Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co.Ltd., Macro Genics, Sichuan Baili Pharmaceutical Co. Ltd., LianBio LLC, Janssen Pharmaceutical, and others.
  • Promising Gastric Cancer Pipeline Therapies in the various stages of development include S-1/Cisplatin, FLX475, Pembrolizumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.
  • December 2023: Hanmi Pharmaceutical Company Limited announced a study of Phase 2 clinical trials for Pembrolizumab and FLX475. This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This study is designed to assess the potential anti-tumor activity when administered at the 100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts.
  • December 2023: Ono Pharmaceuticals Co. Ltd, announced a study of Phase 3 clinical trials for Nivolumab, Oxaliplatin and Capecitabine. The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
  • December 2023: RemeGen Co. Ltd announced a study of Phase 3 clinical trials for RC48-ADC and Apatinib Mesylate Tablets. This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.
  • December 2023: Merck Sharp & Dohme LLC announced a study of Phase 2 clinical trials for Pembrolizumab, Oxaliplatin, and Cisplatin. The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1) positive, human epidermal growth factor receptor 2 (HER2/neu)-negative participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • December 2023: Sanofi announced a study of Phase 3 clinical trials for Docetaxel (XRP6976) and Oxaliplatin (SR96669). Participants in the neoadjuvant chemotherapy arm were treated for 3 cycles (1 cycle is 21 days) before surgery and treated for a year with S-1. Participants in the adjuvant chemotherapy arm underwent surgery and were treated for a year with S-1.

 

Request a sample and discover the recent advances in Gastric Cancer Drugs @ Gastric Cancer Pipeline Outlook Report

 

In the Gastric Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Gastric Cancer clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the Gastric Cancer pipeline products under development.

 

Gastric Cancer Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. About 95% of the time, stomach cancer starts in the stomach lining and progresses slowly. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. Stomach cancer forms when there’s a genetic mutation (change) in the DNA of stomach cells. DNA is the code that tells cells when to grow and when to die. Because of the mutation, the cells grow rapidly and eventually form a tumor instead of dying. The cancer cells overtake healthy cells and may spread to other parts of the body (metastasize).

 

Find out more about Gastric Cancer Analysis @ Gastric Cancer Drugs

 

Gastric Cancer Emerging Drugs

  • Catumaxomab: Linton Pharm Co. Ltd.
  • HLX10: Shanghai Henlius Biotech
  • FLX475: RAPT Therapeutics
  • Savolitinib: AstraZeneca/HUTCHMED
  • ASP 2138: Astellas Pharma
  • Minnelide : Minneamrita Therapeutics LLC

 

Gastric Cancer Therapeutics Assessment

There are approx. 180+ Gastric Cancer companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd. The Gastric Cancer pipeline report proffers an integral view of the emerging Gastric Cancer segmented by stage, product type, molecule type, and route of administration.

 

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Dive deep into rich insights for new Gastric Cancer, visit @ Gastric Cancer Treatment Landscape 

 

Gastric Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Scope of the Gastric Cancer Pipeline Report

  • Coverage- Global
  • Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Gastric Cancer Companies- Linton Pharm Co.Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, TaihoOncology Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co. Ltd, Shanghai MiracogenInc., RemeGen Co Ltd., Idience Co. Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co.Ltd., Macro Genics, Sichuan Baili Pharmaceutical Co. Ltd., LianBio LLC, Janssen Pharmaceutical, and others.
  • Gastric Cancer Pipeline Therapies- S-1/Cisplatin, FLX475, Pembrolizumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.

 

For further information on the Gastric Cancer Pipeline Therapeutics, reach out @ Gastric Cancer Therapeutics Segmentation

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gastric Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. Catumaxomab: Neovii Biotech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. FLX475: RAPT Therapeutics
  12. Early Stage Products (Phase I)
  13. Comparative Analysis
  14. ASP 2138: Astellas Pharma
  15. Inactive Products
  16. Gastric Cancer Key Companies
  17. Gastric Cancer Key Products
  18. Gastric Cancer – Unmet Needs
  19. Gastric Cancer – Market Drivers and Barriers
  20. Gastric Cancer – Future Perspectives and Conclusion
  21. Gastric Cancer Analyst Views
  22. Gastric Cancer Key Companies
  23. Appendix

 

Find out more about Gastric Cancer Therapeutics Assessment @ Gastric Cancer Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastric Cancer Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Colorectal Cancer Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 195+ Colorectal Cancer companies and 200+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Colorectal Cancer Pipeline Report

  • DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ companies working to develop 200+ pipeline Colorectal Cancer.
  • The leading Colorectal Cancer Companies working in the market include Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, LyellI mmunopharma, Genentech, Cantargia AB, Arcus Biosciences Inc., Neogap Therapeutics AB, Criterium Inc., Daiichi Sankyo Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma Ltd., Beyond Bio Inc., Shanghai Henlius Biotech, Rotta pharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Promising Colorectal Cancer Pipeline Therapies in the various stages of development includes CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, Regorafenib (Stivarga, BAY73-4506), Leucovorin, and others.
  • January 2024: Daiichi Sankyo Inc. announced a study of Phase 2 clinical trials for DS-8201a 5.4 mg/kg Q3W. This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
  • December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, and Irinotecan. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
  • December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for BLYG8824A. This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
  • December 2023: Agenus Inc. announced a study of Phase 2 clinical trials for Botensilimab and Balstilimab. This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for Dabrafenib, LTT462, Trametinib, LXH254, and TNO155. A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

 

Request a sample and discover the recent advances in Colorectal Cancer Drugs @ Colorectal Cancer Pipeline Outlook Report

 

In the Colorectal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Colorectal Cancer clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Colorectal Cancer commercial assessment and clinical assessment of the Colorectal Cancer pipeline products under development.

 

Colorectal Cancer Overview

CRC is a multifactorial disease. The epithelial cells of colorectal mucosa can undergo hyperplasia, atypical hyperplasia (mild, moderate, or severe), and adenomas that can eventually develop into carcinoma. This process is usually initiated by carcinogenic factors, causing structural changes in DNA and leading to the malignant transformation of cells into cancer. Morphology includes epithelial hyperplasia, atypical hyperplasia, adenoma formation, carcinoma in situ, and invasive carcinoma.

 

Colorectal Cancer Emerging Drugs

  • XL092 : Exelixis
  • Adagrasb: Mirati Therapeutics
  • Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
  • DS-8201: Daiichi Sankyo
  • Ompenaclid: Inspirna
  • LYL845: Lyell Immunopharma
  • RG6286: Genentech

 

Colorectal Cancer Therapeutics Assessment

There are approx. 195+ Colorectal Cancer companies which are developing the therapies for Colorectal Cancer. The Colorectal Cancer companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Exelixis. The Colorectal Cancer pipeline report proffers an integral view of the emerging Colorectal Cancer segmented by stage, product type, molecule type, and route of administration.

 

Find out more about Colorectal Cancer Analysis @ Colorectal Cancer Drugs

  

DelveInsight’s Colorectal Cancer pipeline report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Colorectal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Dive deep into rich insights for new Colorectal Cancer, visit @ Colorectal Cancer Treatment Landscape

 

Scope of the Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, LyellI mmunopharma, Genentech, Cantargia AB, Arcus Biosciences Inc., Neogap Therapeutics AB, Criterium Inc., Daiichi Sankyo Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma Ltd., Beyond Bio Inc., Shanghai Henlius Biotech, Rotta pharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
  • Colorectal Cancer Pipeline Therapies- CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, Regorafenib (Stivarga, BAY73-4506), Leucovorin, and others.

 

For further information on the Colorectal Cancer Pipeline Therapeutics, reach out @ Colorectal Cancer Therapeutics Segmentation

 

Table of Content

  1. Introduction
  2. Colorectal Cancer Executive Summary
  3. Colorectal Cancer: Overview
  4. Colorectal Cancer Pipeline Therapeutics
  5. Colorectal Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. XL092: Exelixis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Early Stage Products (Phase I)
  12. LYL845: Lyell Immunopharma
  13. Inactive Products
  14. Colorectal Cancer Key Companies
  15. Colorectal Cancer Products
  16. Colorectal Cancer Unmet Needs
  17. Colorectal Cancer Market Drivers and Barriers
  18. Colorectal Cancer Future Perspectives and Conclusion
  19. Colorectal Cancer Analyst Views
  20. Colorectal Cancer Key Companies
  21. Appendix

 

Find out more about Colorectal Cancer Therapeutics Assessment @ Colorectal Cancer Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)